ERBB2 and breast carcinoma: Approximately 15–20% of breast cancers are associated with HER2-positivity, being defined as evidence of HER2 protein overexpression that is measured by immunohistochemistry or by fluorescence in-situ hybridization (FISH) measurement of a HER2 gene copy number of six or more [79].